Last update Sept. 4, 2022

Netupitant

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Aprepitant is a neurokinin-1 receptor antagonist. It is used for the prevention and treatment of nausea and vomiting caused by chemotherapy and surgery. Oral administration in combination with palonosetron.

On latest update relevant data on breastfeeding was not found.

Its very high volume of distribution, and its very high plasma protein binding make excretion into breast milk unlikely.

Side effects are few and usually mild.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

  • Metoclopramide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ondansetron ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Netupitant in other languages or writings:

Groups

Netupitant belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Netupitant in its composition:

  • Akynzeo™. Contains other elements than Netupitant in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 60 %
Molecular weight 579 daltons
Protein Binding 99.5 %
VD 28.3 ± 12.9 l/Kg
Tmax 5 (3 - 6) hours
96 hours

References

  1. EMA. Akynzeo. Ficha técnica. 2020 Full text (in our servers)
  2. Purdue. Akynzeo. Drug Summary. 2017 Full text (in our servers)

Total visits

16,546

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM